Novel Nanoparticle-Based Treatment and Imaging Modalities

Oleh Taratula, Olena R Taratula, Taratula OR
Pharmaceutics · 2023 · vol. 15(1) · doi:10.3390/pharmaceutics15010244 · PMID:36678873 · PMC9861272
Other OA: gold CC-BY-4.0
📄 Open PDF Full text JSON View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-09-25 ⓘ

This paper reviews the widespread use of nanomaterials in cancer research over the last twenty years, focusing on novel nanoparticle-based treatment and imaging modalities.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-08-29 · read from full text ⓘ

The provided text consists exclusively of author declarations, funding acknowledgments, and publisher disclaimers rather than substantive research content. It lists support from various National Institutes of Health institutes but offers no details on study design, methodology, or clinical findings. Consequently, it is impossible to summarize the scientific contributions or results of the paper based on this excerpt alone. The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Over the last twenty years, nanomaterials have been widely used in cancer research [...].
Full text 745 characters · extracted from epmc-fulltextxml · 3 sections · click to expand

Funding

This work was supported by the National Cancer Institute (R01CA237569 and R37CA234006), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD101450) and the National Center for Advancing Translational Sciences of National Institutes of Health (NIH/NCATS) (R03 TR004020-01 and KL2 TR002370).

Fn Group

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Conflicts

The authors declare no conflict of interest.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: epmc-fulltextxml ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-10-11T09:27:45.537177+00:00
pubmed
last seen: 2026-10-08T21:38:24.594406+00:00
License: CC-BY-4.0 · commercial use OK · attribution required
Per Europe PMC